Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Angela Sandre (NPI 1588601157)

Field	Value
Entity Type	Individual
Organization	Angela Sandre
Address	411 Laurel St Ste A300
City	Des Moines
State	IA
ZIP	50314
Taxonomy	Medical Oncology Physician
NPI Enumerated	June 1, 2006

Payer Source	Total Paid
Medicare	$987.4K
Medicaid	$0

Key Findings

This provider is effectively single‑payer in our dataset: total Medicare revenue is $987.4K and there is no Medicaid billing on file. The absence of any Medicaid activity means Medicare drives the entire documented revenue stream and should be treated as the primary payer for underwriting and network negotiations analyses.

Revenue is highly concentrated in a small set of biologic and specialty drug codes — the top 3 Medicare codes account for 66.5% of total Medicare revenue. Those top contributors are J9271 (8.2K claims, $344.4K revenue; 36.3% of Medicare revenue), J0897 (8.7K claims, $156.6K revenue; 16.5%), and J1569 (3.6K claims, $130.7K revenue; 13.8%), indicating most dollars flow from drug administration rather than purely procedural services.

The code mix and volumes point to an infusion‑based oncology/specialty practice model: J9271 (pembrolizumab) and J0897 (denosumab) are high‑cost injectable therapies, and chemotherapy administration codes such as 96413 (303 claims, $28.2K revenue) and infusion codes 96365/96367 appear across the top 25. This pattern aligns with the provider taxonomy of Medical Oncology Physician and suggests operations organized around outpatient infusion services and supportive medication delivery.

Competitive standing for the headline drug codes is mixed: J9271 ranks #1378 of 1841 providers (24th percentile) and is described as "typical, unremarkable volume," while J0897 ranks #1401 of 10057 providers (86th percentile) but is likewise noted as "typical, unremarkable volume." J1569 ranks #265 of 542 providers (51th percentile) and is also characterized as a "typical, unremarkable volume" participant, signaling the provider is not a dominant national leader for these biologics despite sizable local throughput.

Outpatient evaluation & management activity is a notable outlier for this provider: 99214 appears with 1.1K claims and $101K revenue (10.6% of Medicare revenue) and is explicitly labeled an "extreme outlier, far above typical national volume for this code" (rank #8033 of 479517, 98th percentile). High 99214 volume suggests substantial clinic visit throughput and ongoing chronic care management that supports the infusion practice rather than isolated episodic procedures.

Support services and routine diagnostics accompany the infusion workload, with large claim counts for lab and access codes — 80053 (894 claims, $8.9K revenue), 85025 (1K claims, $8.2K revenue), and 36415 (771 claims, $6.2K revenue) — indicating frequent lab monitoring and phlebotomy tied to the therapeutic regimen. These volumes are generally reported as typical relative to national peers (several in the 90%+ rank bands) and reflect an integrated office workflow for infusion patients.

The provider has an established enumeration history (NPI enumerated 2006-06-01, ~20 years ago), which supports interpretation of the pattern as a mature practice rather than a new entrant. Tenure combined with concentrated drug revenue suggests stable referral and prescribing patterns that have persisted over time.

From a payer‑risk perspective, concentration in Medicare and in a few high‑cost injectable drugs creates sensitivity to reimbursement and utilization changes for those agents: top three codes drive 66.5% of Medicare revenue and there is no Medicaid offset. Contracting or policy shifts affecting J9271, J0897, or J1569 could therefore materially impact this provider's revenue profile.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

62 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	8,200	$40	$344.4K
J0897	Injection, denosumab, 1 mg	8,700	$20	$156.6K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	3,630	$40	$130.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,150	$90	$101K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	1,610	$40	$56.4K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	250	$130	$31.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	300	$90	$28.2K
96367	The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose…	430	$20	$9K
80053	The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel.	890	$10	$8.9K
99232	The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or…	150	$60	$8.6K

Showing 1–10 of 62

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 62 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Angela Sandre — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

62 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	23	30	17,200	$40	$902.3K
J1569	3	10	2,680	$40	$133.6K
J0897	23	190	1,920	$20	$74.1K
Q5115	7	10	1,790	$30	$71.4K
96413	26	80	210	$90	$24K
J0185	14	20	6,890	$1	$14.5K
99214	32	4,690	100	$70	$14.4K
99233	355	910	60	$90	$10.5K
99232	549	1,740	80	$60	$9.3K
99213	2,297	4,740	100	$50	$8K

Showing 1–10 of 62

Related Providers

Other providers that share a Tax Identification Number (TIN) with Angela Sandre, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
State University Of Iowa	IA	Family Medicine Physician	$0	$103.8M
State University Of Iowa	IA	General Acute Care Hospital	$0	$90.4M
State University Of Iowa	IA	Dentist	$0	$25.8M
Thomas Buroker	IA	Medical Oncology Physician	$9.4M	$0
Hamilton County Public Hospital	IA	Rural Health Clinic/Center	$0	$8.9M
Kyle Alliman	IA	Ophthalmology Physician	$8.7M	$0
Alex Kartvelishvili	IA	Ophthalmology Physician	$8.1M	$0
Paul Boeke	IA	Ophthalmology Physician	$7.1M	$0
Austin Strohbehn	IA	Retina Specialist (Ophthalmology) Physician	$5.8M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0

Nearby Providers

Other providers in the same ZIP code as Angela Sandre, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Broadlawns Medical Center	IA	General Acute Care Hospital	$0	$112.9M
Catholic Health Initiatives-iowa Corp	IA	General Acute Care Hospital	$0	$26.4M
Des Moines Independent Community School District	IA	Local Education Agency (LEA)	$0	$22.8M
Primary Health Care, Inc.	IA	Federally Qualified Health Center (FQHC)	$0	$14.1M
Broadlawns Medical Center	IA	Community/Behavioral Health Agency	$0	$13.2M
Mercy Clinics Inc	IA	Pediatric Adolescent Medicine Physician	$0	$10.7M
Des Moines River Physicians, LLC	IA	Emergency Medicine Physician	$0	$8.1M
Catholic Health Initiatives-iowa Corp	IA	Clinical Medical Laboratory	$0	$8M
Primary Health Care, Inc.	IA	Federally Qualified Health Center (FQHC)	$0	$7.9M
Vita Health Services	IA	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$7.5M

Angela Sandre — Billing Profile & Reimbursement Data

Sign up for Angela Sandre — Billing Profile & Reimbursement Data policy alerts

Angela Sandre — Billing Profile & Reimbursement Data

Sign up for Angela Sandre — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References